The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials

摘要: Statin therapy has been remarkably successful in reducing coronary events and improving survival. Reduction low-density lipoprotein cholesterol (LDL-C) is the paramount mechanism for benefit of statins. Although relation between reduction risk artery disease pretreatment lipid levels not fully resolved, a feature statin emerging from previous large-scale trials diminished when baseline level LDL-C low (eg, <125 mg/dL). Increases high-density (HDL-C) with are associated mild reductions events, indicating that HDL-C an important element. However, altered by therapy, marked contrast LDL-C. Because most have prevented trials, nonstatin including fibrates, may be necessary to further reduce unacceptably high rate disease.